Then they need to update us. This is idiocy. Anyway, I’m well aware where Dr. Lowdell has consulted, and I’m also well aware that DC therapy has been commercialized previously, as has the use of leukapheresis. Dr. Lowdell wrote that piece primarily about his cell therapy challenges, not those of DCs (nowhere are DCs mentioned). This DC tech is starting in GB, the numbers there are less than 3,000. They can ramp to that in short order. Cognate is artisan as well. It makes sense to transition commercially from tried and true artisan to automated after approval, whereby the prior system acts as a fail safe. They started developing all three types of assays many years ago. Cognate/CRL is much larger and likely soon available.
Linda and others, including DI affirmatively squashed the notion they would start with anything except the artisan method. The UK is a terrific launch pad. They started compassionate there, not the U.S. It makes sense to start commercial there as well. It’s ideal.
Patients are waiting.
Market Data 
Markets 
AI
